{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T06:56:07Z","timestamp":1791701767912,"version":"4.3.4"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/nrurol.2017.181","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T09:37:29Z","timestamp":1510652249000},"page":"42-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Stimulators and activators of soluble guanylate cyclase for urogenital disorders"],"prefix":"10.1038","volume":"15","author":[{"given":"Fabiola Z.","family":"M\u00f3nica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edson","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"BFnrurol2017181_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams, P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21, 167\u2013178 (2002).","journal-title":"Neurourol. Urodyn."},{"key":"BFnrurol2017181_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1124\/pr.56.4.4","volume":"56","author":"KE Andersson","year":"2004","unstructured":"Andersson, K. E. & Wein, A. J. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol. Rev. 56, 581\u2013631 (2004).","journal-title":"Pharmacol. Rev."},{"key":"BFnrurol2017181_CR3","first-page":"145","volume":"9","author":"F Murad","year":"1978","unstructured":"Murad, F., Mittal, C. K., Arnold, W. P., Katsuki, S. & Kimura, H. Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv. Cycl. Nucleotide Res. 9, 145\u2013158 (1978).","journal-title":"Adv. Cycl. Nucleotide Res."},{"key":"BFnrurol2017181_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1124\/pr.110.002907","volume":"62","author":"SH Francis","year":"2010","unstructured":"Francis, S. H., Busch, J. L. & Corbin, J. D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 62, 525\u2013563 (2010).","journal-title":"Pharmacol. Rev."},{"key":"BFnrurol2017181_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/0006-291X(89)92632-6","volume":"161","author":"ME Gold","year":"1989","unstructured":"Gold, M. E., Wood, K. S., Buga, G. M., Byrns, R. E. & Ignarro, L. J. L-Arginine causes whereas L-argininosuccinic acid inhibits endothelium-dependent vascular smooth muscle relaxation. Biochem. Biophys. Res. Commun. 161, 536\u2013543 (1989).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrurol2017181_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/327524a0","volume":"327","author":"RM Palmer","year":"1987","unstructured":"Palmer, R. M., Ferrige, A. G. & Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524\u2013526 (1987).","journal-title":"Nature"},{"key":"BFnrurol2017181_CR7","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/0006-2952(91)90581-O","volume":"42","author":"U Forstermann","year":"1991","unstructured":"Forstermann, U. et al. Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem. Pharmacol. 42, 1849\u20131857 (1991).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrurol2017181_CR8","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.4049\/jimmunol.151.11.6329","volume":"151","author":"JM Griscavage","year":"1993","unstructured":"Griscavage, J. M., Rogers, N. E., Sherman, M. P. & Ignarro, L. J. Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. J. Immunol. 151, 6329\u20136337 (1993).","journal-title":"J. Immunol."},{"key":"BFnrurol2017181_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-biochem-050410-100030","volume":"81","author":"ER Derbyshire","year":"2012","unstructured":"Derbyshire, E. R. & Marletta, M. A. Structure and regulation of soluble guanylate cyclase. Annu. Rev. Biochem. 81, 533\u2013559 (2012).","journal-title":"Annu. Rev. Biochem."},{"key":"BFnrurol2017181_CR10","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1073\/pnas.79.21.6470","volume":"79","author":"RM Rapoport","year":"1982","unstructured":"Rapoport, R. M., Draznin, M. B. & Murad, F. Sodium nitroprusside-induced protein phosphorylation in intact rat aorta is mimicked by 8-bromo cyclic GMP. Proc. Natl Acad. Sci. USA 79, 6470\u20136474 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrurol2017181_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1476-5381.1993.tb13842.x","volume":"110","author":"K Persson","year":"1993","unstructured":"Persson, K., Alm, P., Johansson, K., Larsson, B. & Andersson, K. E. Nitric oxide synthase in pig lower urinary tract: immunohistochemistry, NADPH diaphorase histochemistry and functional effects. Br. J. Pharmacol. 110, 521\u2013530 (1993).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR12","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.2174\/092986711796504646","volume":"18","author":"AY Kots","year":"2011","unstructured":"Kots, A. Y., Bian, K. & Murad, F. Nitric oxide and cyclic GMP signaling pathway as a focus for drug development. Curr. Med. Chem. 18, 3299\u20133305 (2011).","journal-title":"Curr. Med. Chem."},{"key":"BFnrurol2017181_CR13","doi-asserted-by":"publisher","first-page":"e47223","DOI":"10.1371\/journal.pone.0047223","volume":"7","author":"CB Mendes-Silverio","year":"2012","unstructured":"Mendes-Silverio, C. B. et al. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60\u20132770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway. PLoS ONE 7, e47223 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrurol2017181_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/sj.bjp.0704295","volume":"134","author":"N Conran","year":"2001","unstructured":"Conran, N. et al. Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface. Br. J. Pharmacol. 134, 632\u2013638 (2001).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR15","doi-asserted-by":"publisher","first-page":"35008","DOI":"10.1074\/jbc.M601335200","volume":"281","author":"V Jenei","year":"2006","unstructured":"Jenei, V. et al. Nitric oxide produced in response to engagement of \u03b22 integrins on human neutrophils activates the monomeric GTPases Rap1 and Rap2 and promotes adhesion. J. Biol. Chem. 281, 35008\u201335020 (2006).","journal-title":"J. Biol. Chem."},{"key":"BFnrurol2017181_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/sj.bjp.0705661","volume":"141","author":"SM Thomazzi","year":"2004","unstructured":"Thomazzi, S. M., Moreira, J., Marcondes, S., De Nucci, G. & Antunes, E. Role of cyclic GMP on inhibition by nitric oxide donors of human eosinophil chemotaxis in vitro. Br. J. Pharmacol. 141, 653\u2013660 (2004).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR17","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1124\/mol.111.073585","volume":"80","author":"H Zhu","year":"2011","unstructured":"Zhu, H. et al. Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma. Mol. Pharmacol. 80, 1076\u20131084 (2011).","journal-title":"Mol. Pharmacol."},{"key":"BFnrurol2017181_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00424-006-0054-9","volume":"453","author":"P Borst","year":"2007","unstructured":"Borst, P., de Wolf, C. & van de Wetering, K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453, 661\u2013673 (2007).","journal-title":"Pflugers Arch."},{"key":"BFnrurol2017181_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1291\/hypres.27.563","volume":"27","author":"K Kanamasa","year":"2004","unstructured":"Kanamasa, K. et al. Eccentric dosing of nitrates does not increase cardiac events in patients with healed myocardial infarction. Hypertens. Res. 27, 563\u2013572 (2004).","journal-title":"Hypertens. Res."},{"key":"BFnrurol2017181_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1254\/jphs.CRJ06009X","volume":"101","author":"K Bian","year":"2006","unstructured":"Bian, K., Ke, Y., Kamisaki, Y. & Murad, F. Proteomic modification by nitric oxide. J. Pharmacol. Sci. 101, 271\u2013279 (2006).","journal-title":"J. Pharmacol. Sci."},{"key":"BFnrurol2017181_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrd2038","volume":"5","author":"OV Evgenov","year":"2006","unstructured":"Evgenov, O. V. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 5, 755\u2013768 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrurol2017181_CR22","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/S0022-5347(05)65256-1","volume":"167","author":"A Schroder","year":"2002","unstructured":"Schroder, A., Hedlund, P. & Andersson, K. E. Carbon monoxide relaxes the female pig urethra as effectively as nitric oxide in the presence of YC-1. J. Urol. 167, 1892\u20131896 (2002).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR23","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/S0022-5347(05)65142-7","volume":"167","author":"H Mizusawa","year":"2002","unstructured":"Mizusawa, H., Hedlund, P., Brioni, J. D., Sullivan, J. P. & Andersson, K. E. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J. Urol. 167, 2276\u20132281 (2002).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejphar.2010.04.008","volume":"637","author":"FR Bau","year":"2010","unstructured":"Bau, F. R. et al. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41\u20132272 in isolated detrusor smooth muscle. Eur. J. Pharmacol. 637, 171\u2013177 (2010).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrurol2017181_CR25","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/bjp.2008.39","volume":"153","author":"FZ M\u00f3nica","year":"2008","unstructured":"M\u00f3nica, F. Z. et al. Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces \u03b23-adrenoceptor-mediated relaxation, causing rat detrusor overactivity. Br. J. Pharmacol. 153, 1659\u20131668 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/nau.22665","volume":"34","author":"C Fullhase","year":"2015","unstructured":"Fullhase, C. et al. Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41\u20132272 and BAY 60\u20132770 alone or in combination with a phosphodiesterase type 5 inhibitor. Neurourol. Urodyn. 34, 787\u2013793 (2015).","journal-title":"Neurourol. Urodyn."},{"key":"BFnrurol2017181_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.urology.2007.12.031","volume":"72","author":"HA Toque","year":"2008","unstructured":"Toque, H. A., Antunes, E., Teixeira, C. E. & De Nucci, G. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41\u20132272 in the rabbit penile urethra. Urology 72, 711\u2013715 (2008).","journal-title":"Urology"},{"key":"BFnrurol2017181_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.113.211029","volume":"349","author":"EC Alexandre","year":"2014","unstructured":"Alexandre, E. C. et al. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60\u20132770. J. Pharmacol. Exp. Ther. 349, 2\u20139 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrurol2017181_CR29","doi-asserted-by":"publisher","first-page":"312.e9","DOI":"10.1016\/j.urology.2016.04.023","volume":"94","author":"FB Calmasini","year":"2016","unstructured":"Calmasini, F. B. et al. Soluble guanylate cyclase modulators, BAY 41\u20132272 and BAY 60\u20132770, inhibit human and rabbit prostate contractility. Urology 94, 312.e9\u2013312.e15 (2016).","journal-title":"Urology"},{"key":"BFnrurol2017181_CR30","doi-asserted-by":"publisher","first-page":"256.e1","DOI":"10.1016\/j.urology.2013.09.005","volume":"83","author":"R Miyaoka","year":"2014","unstructured":"Miyaoka, R. et al. BAY 41\u20132272, a soluble guanylate cyclase stimulator, relaxes isolated human ureter in a standardized in vitro model. Urology 83, 256.e1\u2013256.e7 (2014).","journal-title":"Urology"},{"key":"BFnrurol2017181_CR31","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.eururo.2011.07.052","volume":"60","author":"A Oudot","year":"2011","unstructured":"Oudot, A. et al. Combination of BAY 60\u20134552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur. Urol. 60, 1020\u20131026 (2011).","journal-title":"Eur. Urol."},{"key":"BFnrurol2017181_CR32","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1743-6109.2012.02912.x","volume":"10","author":"GF Lasker","year":"2013","unstructured":"Lasker, G. F. et al. Analysis of erectile responses to BAY 41\u20138543 and muscarinic receptor stimulation in the rat. J. Sex. Med. 10, 704\u2013718 (2013).","journal-title":"J. Sex. Med."},{"key":"BFnrurol2017181_CR33","doi-asserted-by":"publisher","first-page":"H1393","DOI":"10.1152\/ajpheart.00708.2013","volume":"307","author":"FH Silva","year":"2014","unstructured":"Silva, F. H. et al. Oxidative stress associated with middle aging leads to sympathetic hyperactivity and downregulation of soluble guanylyl cyclase in corpus cavernosum. Am. J. Physiol. Heart Circ. Physiol. 307, H1393\u20131400 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrurol2017181_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jsxm.2016.12.007","volume":"14","author":"K Decaluwe","year":"2017","unstructured":"Decaluwe, K. et al. Erectile dysfunction in heme-deficient nitric oxide-unresponsive soluble guanylate cyclase knock-in mice. J. Sex. Med. 14, 196\u2013204 (2017).","journal-title":"J. Sex. Med."},{"key":"BFnrurol2017181_CR35","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/bju.13105","volume":"116","author":"CS Estancial","year":"2015","unstructured":"Estancial, C. S., Rodrigues, R. L., De Nucci, G., Antunes, E. & M\u00f3nica, F. Z. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60\u20132770 in rabbit corpus cavernosum. BJU Int. 116, 657\u2013664 (2015).","journal-title":"BJU Int."},{"key":"BFnrurol2017181_CR36","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/jsm.12095","volume":"10","author":"M Albersen","year":"2013","unstructured":"Albersen, M., Linsen, L., Tinel, H., Sandner, P. & Van Renterghem, K. Synergistic effects of BAY 60\u20134552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J. Sex. Med. 10, 1268\u20131277 (2013).","journal-title":"J. Sex. Med."},{"key":"BFnrurol2017181_CR37","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1073\/pnas.91.7.2592","volume":"91","author":"B Wedel","year":"1994","unstructured":"Wedel, B. et al. Mutation of His-105 in the \u03b21 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc. Natl Acad. Sci. USA 91, 2592\u20132596 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrurol2017181_CR38","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/35065611","volume":"410","author":"JP Stasch","year":"2001","unstructured":"Stasch, J. P. et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 410, 212\u2013215 (2001).","journal-title":"Nature"},{"key":"BFnrurol2017181_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.bjp.0704484","volume":"135","author":"JP Stasch","year":"2002","unstructured":"Stasch, J. P. et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br. J. Pharmacol. 135, 333\u2013343 (2002).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR40","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1172\/JCI28371","volume":"116","author":"JP Stasch","year":"2006","unstructured":"Stasch, J. P. et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 116, 2552\u20132561 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnrurol2017181_CR41","first-page":"309","volume-title":"Handbook of Experimental Pharmacology","author":"HHHW Schmidt","year":"2009","unstructured":"Schmidt, H. H. H. W., Schmidt, P. M. & Stasch, J. P. in Handbook of Experimental Pharmacology Vol. 191 (eds Schmidt, H. H. H. W., Hofmann, F. & Stasch, J. P.) 309\u2013339 (Springer, 2009)."},{"key":"BFnrurol2017181_CR42","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.1038\/ncomms9482","volume":"6","author":"R Thoonen","year":"2015","unstructured":"Thoonen, R. et al. Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice. Nat. Commun. 6, 8482 (2015).","journal-title":"Nat. Commun."},{"key":"BFnrurol2017181_CR43","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V84.12.4226.bloodjournal84124226","volume":"84","author":"FN Ko","year":"1994","unstructured":"Ko, F. N., Wu, C. C., Kuo, S. C., Lee, F. Y. & Teng, C. M. YC-1, a novel activator of platelet guanylate cyclase. Blood 84, 4226\u20134233 (1994).","journal-title":"Blood"},{"key":"BFnrurol2017181_CR44","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1002\/j.1460-2075.1996.tb01078.x","volume":"15","author":"A Friebe","year":"1996","unstructured":"Friebe, A., Schultz, G. & Koesling, D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 15, 6863\u20136868 (1996).","journal-title":"EMBO J."},{"key":"BFnrurol2017181_CR45","first-page":"277","volume-title":"Handbook of Experimental Pharmacology","author":"JP Stasch","year":"2009","unstructured":"Stasch, J. P. & Hobbs, A. J. in Handbook of Experimental Pharmacology Vol. 191 (eds Schmidt, H. H. H. W., Hofmann, F. & Stasch, J. P.) 277\u2013308 (Springer, 2009)."},{"key":"BFnrurol2017181_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ab.2004.12.025","volume":"339","author":"F Wunder","year":"2005","unstructured":"Wunder, F. et al. A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide\/cGMP pathway. Anal. Biochem. 339, 104\u2013112 (2005).","journal-title":"Anal. Biochem."},{"key":"BFnrurol2017181_CR47","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1016\/j.febslet.2006.06.079","volume":"580","author":"C Rothkegel","year":"2006","unstructured":"Rothkegel, C. et al. Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Lett. 580, 4205\u20134213 (2006).","journal-title":"FEBS Lett."},{"key":"BFnrurol2017181_CR48","first-page":"274","volume":"12","author":"KE Andersson","year":"1994","unstructured":"Andersson, K. E. & Persson, K. Nitric oxide synthase and nitric oxide-mediated effects in lower urinary tract smooth muscles. World J. Urol. 12, 274\u2013280 (1994).","journal-title":"World J. Urol."},{"key":"BFnrurol2017181_CR49","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/BF00698741","volume":"23","author":"HH Iversen","year":"1995","unstructured":"Iversen, H. H., Ehren, I., Gustafsson, L. E., Adolfsson, J. & Wiklund, N. P. Modulation of smooth muscle activity by nitric oxide in the human upper urinary tract. Urol. Res. 23, 391\u2013394 (1995).","journal-title":"Urol. Res."},{"key":"BFnrurol2017181_CR50","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/BF00297196","volume":"22","author":"I Ehren","year":"1994","unstructured":"Ehren, I., Adolfsson, J. & Wiklund, N. P. Nitric oxide synthase activity in the human urogenital tract. Urol. Res. 22, 287\u2013290 (1994).","journal-title":"Urol. Res."},{"key":"BFnrurol2017181_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJM199201093260203","volume":"326","author":"J Rajfer","year":"1992","unstructured":"Rajfer, J., Aronson, W. J., Bush, P. A., Dorey, F. J. & Ignarro, L. J. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. 326, 90\u201394 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2017181_CR52","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1464-410X.2004.04968.x","volume":"94","author":"B Chertin","year":"2004","unstructured":"Chertin, B., Rolle, U., Solari, V., Cascio, S. & Puri, P. The role of nitric oxide in bladder urothelial injury after bladder outlet obstruction. BJU Int. 94, 392\u2013399 (2004).","journal-title":"BJU Int."},{"key":"BFnrurol2017181_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00441-005-1151-3","volume":"321","author":"JI Gillespie","year":"2005","unstructured":"Gillespie, J. I., Markerink-van Ittersum, M. & de Vente, J. Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res. 321, 341\u2013351 (2005).","journal-title":"Cell Tissue Res."},{"key":"BFnrurol2017181_CR54","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1097\/01.ju.0000051882.18132.36","volume":"169","author":"J Gonzalez-Soriano","year":"2003","unstructured":"Gonzalez-Soriano, J. et al. Nitric oxide synthase in the external urethral sphincter of the sheep: immunohistochemical and functional study. J. Urol. 169, 1901\u20131906 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR55","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s11255-015-0964-6","volume":"47","author":"A Otunctemur","year":"2015","unstructured":"Otunctemur, A. et al. The comparison of GLUT-4 and nNOS expression in diabetic and non-diabetic patients with BPH\/LUTS. Int. Urol. Nephrol. 47, 899\u2013904 (2015).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrurol2017181_CR56","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nm0597-571","volume":"3","author":"AL Burnett","year":"1997","unstructured":"Burnett, A. L. et al. Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nat. Med. 3, 571\u2013574 (1997).","journal-title":"Nat. Med."},{"key":"BFnrurol2017181_CR57","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0090-4295(03)00131-6","volume":"61","author":"MA Mamas","year":"2003","unstructured":"Mamas, M. A., Reynard, J. M. & Brading, A. F. Nitric oxide and the lower urinary tract: current concepts, future prospects. Urology 61, 1079\u20131085 (2003).","journal-title":"Urology"},{"key":"BFnrurol2017181_CR58","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0090-4295(99)80012-0","volume":"45","author":"AL Burnett","year":"1995","unstructured":"Burnett, A. L. et al. Characterization and localization of nitric oxide synthase in the human prostate. Urology 45, 435\u2013439 (1995).","journal-title":"Urology"},{"key":"BFnrurol2017181_CR59","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s002400050035","volume":"26","author":"W Bloch","year":"1998","unstructured":"Bloch, W. et al. Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum. Urol. Res. 26, 129\u2013135 (1998).","journal-title":"Urol. Res."},{"key":"BFnrurol2017181_CR60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/sj.ijir.3901256","volume":"16","author":"IF Ghalayini","year":"2004","unstructured":"Ghalayini, I. F. Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility. Int. J. Impot Res. 16, 459\u2013469 (2004).","journal-title":"Int. J. Impot Res."},{"key":"BFnrurol2017181_CR61","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1464-410x.2000.00618.x","volume":"85","author":"FH Mumtaz","year":"2000","unstructured":"Mumtaz, F. H., Khan, M. A., Thompson, C. S., Morgan, R. J. & Mikhailidis, D. P. Nitric oxide in the lower urinary tract: physiology and pathological implications. BJU Int. 85, 611\u2013613 (2000).","journal-title":"BJU Int."},{"key":"BFnrurol2017181_CR62","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/S0022-5347(05)66402-6","volume":"165","author":"B Fathian-Sabet","year":"2001","unstructured":"Fathian-Sabet, B. et al. Localization of constitutive nitric oxide synthase isoforms and the nitric oxide target enzyme soluble guanylyl cyclase in the human bladder. J. Urol. 165, 1724\u20131729 (2001).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR63","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/nau.22990","volume":"36","author":"FB Calmasini","year":"2017","unstructured":"Calmasini, F. B. et al. Implication of Rho-kinase and soluble guanylyl cyclase enzymes in prostate smooth muscle dysfunction in middle-aged rats. Neurourol. Urodyn. 36, 589\u2013596 (2017).","journal-title":"Neurourol. Urodyn."},{"key":"BFnrurol2017181_CR64","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0006-2952(99)00381-0","volume":"59","author":"S Behrends","year":"2000","unstructured":"Behrends, S., Steenpass, A., Porst, H. & Scholz, H. Expression of nitric oxide-sensitive guanylyl cyclase subunits in human corpus cavernosum. Biochem. Pharmacol. 59, 713\u2013717 (2000).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrurol2017181_CR65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.ijir.3900524","volume":"12","author":"T Klotz","year":"2000","unstructured":"Klotz, T. et al. Soluble guanylate cyclase and cGMP-dependent protein kinase I expression in the human corpus cavernosum. Int. J. Impot. Res. 12, 157\u2013164 (2000).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol2017181_CR66","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1111\/jsm.12682","volume":"11","author":"FH Silva","year":"2014","unstructured":"Silva, F. H. et al. Prolonged therapy with the soluble guanylyl cyclase activator BAY 60\u20132770 restores the erectile function in obese mice. J. Sex. Med. 11, 2661\u20132670 (2014).","journal-title":"J. Sex. Med."},{"key":"BFnrurol2017181_CR67","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1530\/REP-10-0517","volume":"142","author":"D Muller","year":"2011","unstructured":"Muller, D., Mukhopadhyay, A. K., Davidoff, M. S. & Middendorff, R. Cyclic GMP signaling in rat urinary bladder, prostate, and epididymis: tissue-specific changes with aging and in response to Leydig cell depletion. Reproduction 142, 333\u2013343 (2011).","journal-title":"Reproduction"},{"key":"BFnrurol2017181_CR68","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.juro.2013.09.020","volume":"191","author":"LO Leiria","year":"2014","unstructured":"Leiria, L. O. et al. The soluble guanylyl cyclase activator BAY 60\u20132770 ameliorates overactive bladder in obese mice. J. Urol. 191, 539\u2013547 (2014).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR69","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0022-5347(17)37208-7","volume":"147","author":"KE Andersson","year":"1992","unstructured":"Andersson, K. E., Garcia Pascual, A., Persson, K., Forman, A. & Tottrup, A. Electrically-induced, nerve-mediated relaxation of rabbit urethra involves nitric oxide. J. Urol. 147, 253\u2013259 (1992).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR70","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1748-1716.1991.tb09114.x","volume":"141","author":"A Garcia-Pascual","year":"1991","unstructured":"Garcia-Pascual, A., Costa, G., Garcia-Sacristan, A. & Andersson, K. E. Relaxation of sheep urethral muscle induced by electrical stimulation of nerves: involvement of nitric oxide. Acta Physiol. Scand. 141, 531\u2013539 (1991).","journal-title":"Acta Physiol. Scand."},{"key":"BFnrurol2017181_CR71","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0014-2999(93)90451-M","volume":"231","author":"S Hashimoto","year":"1993","unstructured":"Hashimoto, S., Kigoshi, S. & Muramatsu, I. Nitric oxide-dependent and -independent neurogenic relaxation of isolated dog urethra. Eur. J. Pharmacol. 231, 209\u2013214 (1993).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrurol2017181_CR72","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/j.1476-5381.1995.tb16379.x","volume":"116","author":"V Werkstrom","year":"1995","unstructured":"Werkstrom, V. et al. Factors involved in the relaxation of female pig urethra evoked by electrical field stimulation. Br. J. Pharmacol. 116, 1599\u20131604 (1995).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sj.bjp.0704050","volume":"133","author":"H Masuda","year":"2001","unstructured":"Masuda, H. et al. Involvement of accumulated endogenous NOS inhibitors and decreased NOS activity in the impaired neurogenic relaxation of the rabbit proximal urethra with ischaemia. Br. J. Pharmacol. 133, 97\u2013106 (2001).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR74","doi-asserted-by":"publisher","first-page":"R1112","DOI":"10.1152\/ajpregu.2000.279.3.R1112","volume":"279","author":"K Persson","year":"2000","unstructured":"Persson, K. et al. Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1112\u2013R1120 (2000).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"BFnrurol2017181_CR75","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1046\/j.1464-410X.2003.04161.x","volume":"91","author":"MO Fraser","year":"2003","unstructured":"Fraser, M. O. & Chancellor, M. B. Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. BJU Int. 91, 743\u2013748 (2003).","journal-title":"BJU Int."},{"key":"BFnrurol2017181_CR76","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2125.1993.tb04152.x","volume":"35","author":"MJ James","year":"1993","unstructured":"James, M. J., Birmingham, A. T. & Hill, S. J. Partial mediation by nitric oxide of the relaxation of human isolated detrusor strips in response to electrical field stimulation. Br. J. Clin. Pharmacol. 35, 366\u2013372 (1993).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrurol2017181_CR77","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0022-5347(05)65135-X","volume":"167","author":"H Masuda","year":"2002","unstructured":"Masuda, H. et al. Localization and role of nitric oxide synthase and endogenous nitric oxide synthase inhibitors in the rabbit lower urinary tract. J. Urol. 167, 2235\u20132240 (2002).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR78","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1152\/physrev.00038.2003","volume":"84","author":"KE Andersson","year":"2004","unstructured":"Andersson, K. E. & Arner, A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol. Rev. 84, 935\u2013986 (2004).","journal-title":"Physiol. Rev."},{"key":"BFnrurol2017181_CR79","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0022-5347(05)68352-8","volume":"162","author":"OR Hayek","year":"1999","unstructured":"Hayek, O. R. et al. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity. J. Urol. 162, 1527\u20131531 (1999).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR80","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1111\/j.1476-5381.1995.tb15104.x","volume":"116","author":"M Takeda","year":"1995","unstructured":"Takeda, M. & Lepor, H. Nitric oxide synthase in dog urethra: a histochemical and pharmacological analysis. Br. J. Pharmacol. 116, 2517\u20132523 (1995).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/pros.1079","volume":"48","author":"K Aikawa","year":"2001","unstructured":"Aikawa, K., Yokota, T., Okamura, H. & Yamaguchi, O. Endogenous nitric oxide-mediated relaxation and nitrinergic innervation in the rabbit prostate: the changes with aging. Prostate 48, 40\u201346 (2001).","journal-title":"Prostate"},{"key":"BFnrurol2017181_CR82","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0014-2999(97)01270-3","volume":"337","author":"AT Najbar-Kaszkiel","year":"1997","unstructured":"Najbar-Kaszkiel, A. T., Di Iulio, J. L., Li, C. G. & Rand, M. J. Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs. Eur. J. Pharmacol. 337, 251\u2013258 (1997).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrurol2017181_CR83","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S0090-4295(99)80013-2","volume":"45","author":"M Takeda","year":"1995","unstructured":"Takeda, M., Tang, R., Shapiro, E., Burnett, A. L. & Lepor, H. Effects of nitric oxide on human and canine prostates. Urology 45, 440\u2013446 (1995).","journal-title":"Urology"},{"key":"BFnrurol2017181_CR84","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.pharmthera.2005.10.011","volume":"111","author":"G Cirino","year":"2006","unstructured":"Cirino, G., Fusco, F., Imbimbo, C. & Mirone, V. Pharmacology of erectile dysfunction in man. Pharmacol. Ther. 111, 400\u2013423 (2006).","journal-title":"Pharmacol. Ther."},{"key":"BFnrurol2017181_CR85","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/nrurol.2013.101","volume":"10","author":"MS Rahnama'i","year":"2013","unstructured":"Rahnama'i, M. S., Uckert, S., Hohnen, R. & van Koeveringe, G. A. The role of phosphodiesterases in bladder pathophysiology. Nat. Rev. Urol. 10, 414\u2013424 (2013).","journal-title":"Nat. Rev. Urol."},{"key":"BFnrurol2017181_CR86","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.eururo.2011.08.005","volume":"60","author":"H Porst","year":"2011","unstructured":"Porst, H. et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur. Urol. 60, 1105\u20131113 (2011).","journal-title":"Eur. Urol."},{"key":"BFnrurol2017181_CR87","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1442-2042.2011.02772.x","volume":"18","author":"G Maselli","year":"2011","unstructured":"Maselli, G. et al. Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study. Int. J. Urol. 18, 515\u2013520 (2011).","journal-title":"Int. J. Urol."},{"key":"BFnrurol2017181_CR88","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","volume":"70","author":"M Gacci","year":"2016","unstructured":"Gacci, M. et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur. Urol. 70, 124\u2013133 (2016).","journal-title":"Eur. Urol."},{"key":"BFnrurol2017181_CR89","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0090-4295(01)00988-8","volume":"57","author":"MH Blanker","year":"2001","unstructured":"Blanker, M. H. et al. Voided volumes: normal values and relation to lower urinary tract symptoms in elderly men, a community-based study. Urology 57, 1093\u20131099 (2001).","journal-title":"Urology"},{"key":"BFnrurol2017181_CR90","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.ijir.3901526","volume":"19","author":"R Shiri","year":"2007","unstructured":"Shiri, R. et al. Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother. Int. J. Impot. Res. 19, 317\u2013320 (2007).","journal-title":"Int. J. Impot. Res."},{"key":"BFnrurol2017181_CR91","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.juro.2007.08.167","volume":"179","author":"ST Brookes","year":"2008","unstructured":"Brookes, S. T., Link, C. L., Donovan, J. L. & McKinlay, J. B. Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health Survey. J. Urol. 179, 250\u2013255 (2008).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR92","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrurol.2015.301","volume":"13","author":"L Vignozzi","year":"2016","unstructured":"Vignozzi, L., Gacci, M. & Maggi, M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat. Rev. Urol. 13, 108\u2013119 (2016).","journal-title":"Nat. Rev. Urol."},{"key":"BFnrurol2017181_CR93","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.eururo.2011.07.040","volume":"60","author":"JK Parsons","year":"2011","unstructured":"Parsons, J. K. et al. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study. Eur. Urol. 60, 1173\u20131180 (2011).","journal-title":"Eur. Urol."},{"key":"BFnrurol2017181_CR94","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.juro.2011.07.067","volume":"186","author":"DF Penson","year":"2011","unstructured":"Penson, D. F., Munro, H. M., Signorello, L. B., Blot, W. J. & Fowke, J. H. Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. J. Urol. 186, 2316\u20132322 (2011).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR95","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.juro.2013.07.005","volume":"191","author":"NN Maserejian","year":"2014","unstructured":"Maserejian, N. N. et al. Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample. J. Urol. 191, 107\u2013113 (2014).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR96","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1464-410X.2011.10819.x","volume":"110","author":"RK Lee","year":"2012","unstructured":"Lee, R. K., Chung, D., Chughtai, B., Te, A. E. & Kaplan, S. A. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int. 110, 540\u2013545 (2012).","journal-title":"BJU Int."},{"key":"BFnrurol2017181_CR97","doi-asserted-by":"publisher","first-page":"F887","DOI":"10.1152\/ajprenal.00489.2016","volume":"312","author":"F Daneshgari","year":"2017","unstructured":"Daneshgari, F., Liu, G. & Hanna-Mitchell, A. T. Path of translational discovery of urological complications of obesity and diabetes. Am. J. Physiol. Renal Physiol. 312, F887\u2013F896 (2017).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrurol2017181_CR98","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cca.2006.01.019","volume":"370","author":"H Nandeesha","year":"2006","unstructured":"Nandeesha, H., Koner, B. C., Dorairajan, L. N. & Sen, S. K. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin. Chim. Acta 370, 89\u201393 (2006).","journal-title":"Clin. Chim. Acta"},{"key":"BFnrurol2017181_CR99","first-page":"1140","volume":"76","author":"A Vermeulen","year":"1993","unstructured":"Vermeulen, A., Kaufman, J. M., Deslypere, J. P. & Thomas, G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J. Clin. Endocrinol. Metab. 76, 1140\u20131146 (1993).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrurol2017181_CR100","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0306-9877(98)90006-8","volume":"50","author":"PG Cohen","year":"1998","unstructured":"Cohen, P. G. The role of estradiol in the maintenance of secondary hypogonadism in males in erectile dysfunction. Med. Hypotheses 50, 331\u2013333 (1998).","journal-title":"Med. Hypotheses"},{"key":"BFnrurol2017181_CR101","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0026-0495(03)00186-0","volume":"52","author":"B Zumoff","year":"2003","unstructured":"Zumoff, B., Miller, L. K. & Strain, G. W. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 52, 1126\u20131128 (2003).","journal-title":"Metabolism"},{"key":"BFnrurol2017181_CR102","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jsxm.2016.06.004","volume":"13","author":"CA Podlasek","year":"2016","unstructured":"Podlasek, C. A. et al. Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction. J. Sex. Med. 13, 1183\u20131198 (2016).","journal-title":"J. Sex. Med."},{"key":"BFnrurol2017181_CR103","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2017.02.022","volume":"72","author":"V Mirone","year":"2017","unstructured":"Mirone, V. et al. European Association of Urology Position Statement on the Role of the Urologist in the Management of Male Hypogonadism and Testosterone Therapy. Eur. Urol. 72, 164\u2013167 (2017).","journal-title":"Eur. Urol."},{"key":"BFnrurol2017181_CR104","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","volume":"374","author":"PJ Snyder","year":"2016","unstructured":"Snyder, P. J. et al. Effects of Testosterone Treatment in Older Men. N. Engl. J. Med. 374, 611\u2013624 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2017181_CR105","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/bju.13516","volume":"118","author":"G Hackett","year":"2016","unstructured":"Hackett, G. et al. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU Int. 118, 804\u2013813 (2016).","journal-title":"BJU Int."},{"key":"BFnrurol2017181_CR106","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1097\/01.ju.0000121283.92963.05","volume":"171","author":"K Torimoto","year":"2004","unstructured":"Torimoto, K. et al. Urethral dysfunction in diabetic rats. J. Urol. 171, 1959\u20131964 (2004).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR107","doi-asserted-by":"publisher","first-page":"R1728","DOI":"10.1152\/ajpregu.00654.2005","volume":"290","author":"F Daneshgari","year":"2006","unstructured":"Daneshgari, F. et al. Temporal differences in bladder dysfunction caused by diabetes, diuresis, and treated diabetes in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R1728\u20131735 (2006).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"BFnrurol2017181_CR108","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.juro.2008.08.002","volume":"180","author":"M Saito","year":"2008","unstructured":"Saito, M. et al. Pharmacological properties, functional alterations and gene expression of muscarinic receptors in young and old type 2 Goto-Kakizaki diabetic rat bladders. J. Urol. 180, 2701\u20132705 (2008).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR109","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1124\/jpet.108.144907","volume":"328","author":"K Nobe","year":"2009","unstructured":"Nobe, K., Yamazaki, T., Tsumita, N., Hashimoto, T. & Honda, K. Glucose-dependent enhancement of diabetic bladder contraction is associated with a rho kinase-regulated protein kinase C pathway. J. Pharmacol. Exp. Ther. 328, 940\u2013950 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrurol2017181_CR110","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0163-7258(97)00038-7","volume":"75","author":"WH Turner","year":"1997","unstructured":"Turner, W. H. & Brading, A. F. Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment. Pharmacol. Ther. 75, 77\u2013110 (1997).","journal-title":"Pharmacol. Ther."},{"key":"BFnrurol2017181_CR111","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/j.1476-5381.2011.01311.x","volume":"163","author":"LO Leiria","year":"2011","unstructured":"Leiria, L. O. et al. Functional, morphological and molecular characterization of bladder dysfunction in streptozotocin-induced diabetic mice: evidence of a role for L-type voltage-operated Ca2+ channels. Br. J. Pharmacol. 163, 1276\u20131288 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR112","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1016\/j.juro.2008.01.086","volume":"179","author":"WC Lee","year":"2008","unstructured":"Lee, W. C., Chien, C. T., Yu, H. J. & Lee, S. W. Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. J. Urol. 179, 2470\u20132476 (2008).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR113","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1111\/j.1464-410X.2010.09704.x","volume":"107","author":"HA Toque","year":"2011","unstructured":"Toque, H. A. et al. High-fat diet associated with obesity induces impairment of mouse corpus cavernosum responses. BJU Int. 107, 1628\u20131634 (2011).","journal-title":"BJU Int."},{"key":"BFnrurol2017181_CR114","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1124\/jpet.114.220970","volume":"353","author":"KP Nunes","year":"2015","unstructured":"Nunes, K. P., Teixeira, C. E., Priviero, F. B., Toque, H. A. & Webb, R. C. Beneficial effect of the soluble guanylyl cyclase stimulator BAY 41\u20132272 on impaired penile erection in db\/db\u2212\/\u2212 type II diabetic and obese mice. J. Pharmacol. Exp. Ther. 353, 330\u2013339 (2015).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrurol2017181_CR115","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.phrs.2016.06.029","volume":"111","author":"Z Zhou","year":"2016","unstructured":"Zhou, Z. et al. Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide. Pharmacol. Res. 111, 556\u2013562 (2016).","journal-title":"Pharmacol. Res."},{"key":"BFnrurol2017181_CR116","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1113\/jphysiol.2013.251843","volume":"591","author":"LO Leiria","year":"2013","unstructured":"Leiria, L. O. et al. Insulin relaxes bladder via PI3K\/AKT\/eNOS pathway activation in mucosa: unfolded protein response-dependent insulin resistance as a cause of obesity-associated overactive bladder. J. Physiol. 591, 2259\u20132273 (2013).","journal-title":"J. Physiol."},{"key":"BFnrurol2017181_CR117","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1126\/science.1103160","volume":"306","author":"U Ozcan","year":"2004","unstructured":"Ozcan, U. et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457\u2013461 (2004).","journal-title":"Science"},{"key":"BFnrurol2017181_CR118","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1442-2042.2004.00791.x","volume":"11","author":"K Yoshimura","year":"2004","unstructured":"Yoshimura, K. et al. Prevalence of and risk factors for nocturia: analysis of a health screening program. Int. J. Urol. 11, 282\u2013287 (2004).","journal-title":"Int. J. Urol."},{"key":"BFnrurol2017181_CR119","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2006.01.031","volume":"50","author":"A Ponholzer","year":"2006","unstructured":"Ponholzer, A., Temml, C., Wehrberger, C., Marszalek, M. & Madersbacher, S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur. Urol. 50, 581\u2013586 (2006).","journal-title":"Eur. Urol."},{"key":"BFnrurol2017181_CR120","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2016.08.087","volume":"197","author":"O Yokoyama","year":"2017","unstructured":"Yokoyama, O. et al. Nocturnal polyuria and hypertension in patients with lifestyle related diseases and overactive bladder. J. Urol. 197, 423\u2013431 (2017).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR121","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejphar.2014.05.038","volume":"738","author":"AC Ramos-Filho","year":"2014","unstructured":"Ramos-Filho, A. C. et al. Blockade of renin-angiotensin system prevents micturition dysfunction in renovascular hypertensive rats. Eur. J. Pharmacol. 738, 285\u2013292 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrurol2017181_CR122","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/01.HYP.20.3.298","volume":"20","author":"MO Ribeiro","year":"1992","unstructured":"Ribeiro, M. O., Antunes, E., de Nucci, G., Lovisolo, S. M. & Zatz, R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20, 298\u2013303 (1992).","journal-title":"Hypertension"},{"key":"BFnrurol2017181_CR123","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1476-5381.1992.tb14483.x","volume":"107","author":"K Persson","year":"1992","unstructured":"Persson, K., Igawa, Y., Mattiasson, A. & Andersson, K. E. Effects of inhibition of the L-arginine\/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br. J. Pharmacol. 107, 178\u2013184 (1992).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR124","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejphar.2015.03.057","volume":"758","author":"FB Calmasini","year":"2015","unstructured":"Calmasini, F. B. et al. Increased Rho-kinase-mediated prostate contractions associated with impairment of beta-adrenergic-cAMP-signaling pathway by chronic nitric oxide deficiency. Eur. J. Pharmacol. 758, 24\u201330 (2015).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrurol2017181_CR125","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1464-410X.2010.09776.x","volume":"108","author":"MA Claudino","year":"2011","unstructured":"Claudino, M. A. et al. Long-term oral treatment with BAY 41\u20132272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model. BJU Int. 108, 116\u2013122 (2011).","journal-title":"BJU Int."},{"key":"BFnrurol2017181_CR126","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1124\/jpet.107.124594","volume":"322","author":"CE Teixeira","year":"2007","unstructured":"Teixeira, C. E., Priviero, F. B. & Webb, R. C. Effects of 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrim idin-4-ylamine (BAY 41\u20132272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity\/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice. J. Pharmacol. Exp. Ther. 322, 1093\u20131102 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrurol2017181_CR127","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrurol.2011.112","volume":"8","author":"J Hammarsten","year":"2011","unstructured":"Hammarsten, J. & Peeker, R. Urological aspects of the metabolic syndrome. Nat. Rev. Urol. 8, 483\u2013494 (2011).","journal-title":"Nat. Rev. Urol."},{"key":"BFnrurol2017181_CR128","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/jsm.12063","volume":"10","author":"FH Silva","year":"2013","unstructured":"Silva, F. H. et al. Superoxide anion production by NADPH oxidase plays a major role in erectile dysfunction in middle-aged rats: prevention by antioxidant therapy. J. Sex. Med. 10, 960\u2013971 (2013).","journal-title":"J. Sex. Med."},{"key":"BFnrurol2017181_CR129","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1743-6109.2009.01511.x","volume":"7","author":"B Fibbi","year":"2010","unstructured":"Fibbi, B. et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J. Sex. Med. 7, 59\u201369 (2010).","journal-title":"J. Sex. Med."},{"key":"BFnrurol2017181_CR130","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)64009-8","volume":"169","author":"JS Kalsi","year":"2003","unstructured":"Kalsi, J. S. et al. BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J. Urol. 169, 761\u2013766 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR131","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejphar.2003.08.012","volume":"477","author":"JS Baracat","year":"2003","unstructured":"Baracat, J. S. et al. Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41\u20132272 in human and rabbit corpus cavernosum. Eur. J. Pharmacol. 477, 163\u2013169 (2003).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrurol2017181_CR132","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0090-4295(02)02121-0","volume":"61","author":"E Bischoff","year":"2003","unstructured":"Bischoff, E., Schramm, M., Straub, A., Feurer, A. & Stasch, J. P. BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 61, 464\u2013467 (2003).","journal-title":"Urology"},{"key":"BFnrurol2017181_CR133","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/sj.ijir.3901627","volume":"20","author":"S Nimmegeers","year":"2008","unstructured":"Nimmegeers, S. et al. Role of the soluble guanylyl cyclase alpha1-subunit in mice corpus cavernosum smooth muscle relaxation. Int. J. Impot Res. 20, 278\u2013284 (2008).","journal-title":"Int. J. Impot Res."},{"key":"BFnrurol2017181_CR134","doi-asserted-by":"publisher","first-page":"H1670","DOI":"10.1152\/ajpheart.00062.2013","volume":"304","author":"GF Lasker","year":"2013","unstructured":"Lasker, G. F. et al. The sGC activator BAY 60\u20132770 has potent erectile activity in the rat. Am. J. Physiol. Heart Circ. Physiol. 304, H1670\u2013H1679 (2013).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrurol2017181_CR135","doi-asserted-by":"publisher","first-page":"L323","DOI":"10.1152\/ajplung.00442.2009","volume":"299","author":"RS Stephens","year":"2010","unstructured":"Stephens, R. S. et al. cGMP increases antioxidant function and attenuates oxidant cell death in mouse lung microvascular endothelial cells by a protein kinase G-dependent mechanism. Am. J. Physiol. Lung Cell. Mol. Physiol. 299, L323\u2013L333 (2010).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"BFnrurol2017181_CR136","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1476-5381.2009.00263.x","volume":"157","author":"LS Hoffmann","year":"2009","unstructured":"Hoffmann, L. S. et al. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br. J. Pharmacol. 157, 781\u2013795 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR137","doi-asserted-by":"publisher","first-page":"22651","DOI":"10.1074\/jbc.M110.111559","volume":"285","author":"F Martin","year":"2010","unstructured":"Martin, F. et al. Structure of cinaciguat (BAY 58\u20132667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J. Biol. Chem. 285, 22651\u201322657 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFnrurol2017181_CR138","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1021\/bi301657w","volume":"52","author":"V Kumar","year":"2013","unstructured":"Kumar, V. et al. Insights into BAY 60\u20132770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes. Biochemistry 52, 3601\u20133608 (2013).","journal-title":"Biochemistry"},{"issue":"Suppl. 2","key":"BFnrurol2017181_CR139","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1038\/sj.bjp.0706630","volume":"147","author":"G McMurray","year":"2006","unstructured":"McMurray, G., Casey, J. H. & Naylor, A. M. Animal models in urological disease and sexual dysfunction. Br. J. Pharmacol. 147 (Suppl. 2), S62\u2013S79 (2006).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2017181_CR140","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1097\/01.ju.0000070926.39442.4c","volume":"170","author":"A Schroder","year":"2003","unstructured":"Schroder, A., Uvelius, B., Newgreen, D. & Andersson, K. E. Bladder overactivity in mice after 1 week of outlet obstruction. Mainly afferent dysfunction? J. Urol. 170, 1017\u20131021 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR141","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","volume":"193","author":"PM Hanno","year":"2015","unstructured":"Hanno, P. M., Erickson, D., Moldwin, R. & Faraday, M. M. Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment. J. Urol. 193, 1545\u20131553 (2015).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR142","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","volume":"53","author":"JP van de Merwe","year":"2008","unstructured":"van de Merwe, J. P. et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: an ESSIC proposal. Eur. Urol. 53, 60\u201367 (2008).","journal-title":"Eur. Urol."},{"key":"BFnrurol2017181_CR143","doi-asserted-by":"publisher","first-page":"F85","DOI":"10.1152\/ajprenal.00041.2016","volume":"311","author":"MG de Oliveira","year":"2016","unstructured":"de Oliveira, M. G. et al. Activation of soluble guanylyl cyclase by BAY 58\u20132667 improves bladder function in cyclophosphamide-induced cystitis in mice. Am. J. Physiol. Renal Physiol. 311, F85\u2013F93 (2016).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrurol2017181_CR144","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejim.2013.01.001","volume":"24","author":"RA Condorelli","year":"2013","unstructured":"Condorelli, R. A. et al. Arterial erectile dysfunction: different severities of endothelial apoptosis between diabetic patients \u201cresponders\u201d and \u201cnon responders\u201d to sildenafil. Eur. J. Intern. Med. 24, 234\u2013240 (2013).","journal-title":"Eur. J. Intern. Med."},{"key":"BFnrurol2017181_CR145","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1111\/j.1464-410X.2009.09084.x","volume":"105","author":"FS Lizarte","year":"2010","unstructured":"Lizarte, F. S. et al. Chronic alcoholism associated with diabetes impairs erectile function in rats. BJU Int. 105, 1592\u20131597 (2010).","journal-title":"BJU Int."},{"key":"BFnrurol2017181_CR146","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0094-0143(21)00692-3","volume":"22","author":"GJ Christ","year":"1995","unstructured":"Christ, G. J. The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Urol. Clin. North Am. 22, 727\u2013745 (1995).","journal-title":"Urol. Clin. North Am."},{"key":"BFnrurol2017181_CR147","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrurol.2015.174","volume":"12","author":"NM Fried","year":"2015","unstructured":"Fried, N. M. & Burnett, A. L. Novel methods for mapping the cavernous nerves during radical prostatectomy. Nat. Rev. Urol. 12, 451\u2013460 (2015).","journal-title":"Nat. Rev. Urol."},{"key":"BFnrurol2017181_CR148","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/0140-6736(92)92687-B","volume":"340","author":"JP Kinsella","year":"1992","unstructured":"Kinsella, J. P., Neish, S. R., Shaffer, E. & Abman, S. H. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340, 819\u2013820 (1992).","journal-title":"Lancet"},{"key":"BFnrurol2017181_CR149","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1542\/peds.91.5.997","volume":"91","author":"JP Kinsella","year":"1993","unstructured":"Kinsella, J. P. & Abman, S. H. Inhalational nitric oxide therapy for persistent pulmonary hypertension of the newborn. Pediatrics 91, 997\u2013998 (1993).","journal-title":"Pediatrics"},{"key":"BFnrurol2017181_CR150","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","volume":"141","author":"D Montani","year":"2014","unstructured":"Montani, D. et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol. Ther. 141, 172\u2013119 (2014).","journal-title":"Pharmacol. Ther."},{"key":"BFnrurol2017181_CR151","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","volume":"74","author":"C Beyer","year":"2015","unstructured":"Beyer, C. et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling. Ann. Rheum. Dis. 74, 1408\u20131416 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrurol2017181_CR152","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.juro.2008.06.079","volume":"180","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn, C. G., McVary, K. T., Elion-Mboussa, A. & Viktrup, L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J. Urol. 180, 1228\u20131234 (2008).","journal-title":"J. Urol."},{"key":"BFnrurol2017181_CR153","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00855465 (2016)."},{"key":"BFnrurol2017181_CR154","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00810693 (2016)."},{"key":"BFnrurol2017181_CR155","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1183\/09031936.00105914","volume":"45","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8, N., M\u00fcller, K., Scalise, A.-V. & Gr\u00fcnig, E. Patent Plus: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur. Respir. J. 45, 1314\u20131322 (2008).","journal-title":"Eur. Respir. J."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2017.181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2017.181","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrurol.2017.181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2017.181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:15:21Z","timestamp":1693228521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2017.181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFnrurol2017181"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2017.181","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]},"assertion":[{"value":"14 November 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}